Amrutanjan Health Care Limited (AMRUTANJAN:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Amrutanjan Health Care Limited stock forecast from 0 analysts, the average analyst target price for Amrutanjan Health Care Limited is not available over the next 12 months. Amrutanjan Health Care Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amrutanjan Health Care Limited is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Amrutanjan Health Care Limited’s stock price was INR 638.20. Amrutanjan Health Care Limited’s stock price has changed by -1.58% over the past week, +3.32% over the past month and +2.28% over the last year.
No recent analyst target price found for Amrutanjan Health Care Limited
No recent average analyst rating found for Amrutanjan Health Care Limited
Company Overview Amrutanjan Health Care Limited
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons, stick-on patch, body pain gels, and joint muscle sprays. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; dental gel; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, Southeast Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India. Address: No.103 (Old No.42-45), Luz Church Road, Chennai, India, 600004 Read Less
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll...Read More
Frequently Asked Questions About Amrutanjan Health Care Limited (AMRUTANJAN:NSE) Stock
Stock Target Advisor's fundamental analysis for Amrutanjan Health Care Limited's stock is Slightly Bearish.
AMRUTANJAN:NSE stock's dividend yield is 0.87%.
Our analysis grades AMRUTANJAN:NSE stock's dividend yield at B-. This means that AMRUTANJAN:NSE stock's dividend yield is above 81% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AMRUTANJAN:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on AMRUTANJAN:NSE's stock to indicate what its average analyst target is.
AMRUTANJAN:NSE stock's Price/Earning ratio is 42.21.
Our analysis grades AMRUTANJAN:NSE stock's Price / Earning ratio at F. This means that AMRUTANJAN:NSE stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AMRUTANJAN:NSE may be a overvalued for its sector.
The last closing price of AMRUTANJAN:NSE's stock was INR 638.20.
The most recent market capitalization for AMRUTANJAN:NSE is INR 18.45B.
Unfortunately we do not have enough analyst data on AMRUTANJAN:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Amrutanjan Health Care Limited's stock.
As per our most recent records Amrutanjan Health Care Limited has 537 Employees.
Amrutanjan Health Care Limited's registered address is No.103 (Old No.42-45), Luz Church Road, Chennai, India, 600004.
You can get more information about it from Amrutanjan Health Care Limited's website at https://www.amrutanjan.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMRUTANJAN:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
